Company Overview
Neurocrine Biosciences, Inc. is engaged in the discovery, development, and commercialization of pharmaceuticals designed to treat neurological, psychiatric, endocrine, and immunological disorders within the United States and international markets. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized therapeutic areas rather than broad consumer markets. Its operational scale is substantial, characterized by a market capitalization of $13.02B, annual revenue of $2.86B, and a workforce comprising 2,000 employees. These valuation and revenue figures indicate that Neurocrine Biosciences holds a significant position in its niche, possessing the financial resources and human capital necessary to sustain extensive research and development programs for complex medical conditions.
Financial Health
The company reported a trailing twelve-month revenue of $2.86B, generating net income of $478.60M and an EBITDA of $666.60M. The substantial gap between revenue and net income reveals a cost structure where total operating expenses and taxes consumed approximately 83.3% of gross revenue, leaving a profit margin of 16.7%. Neurocrine Biosciences generated free cash flow of $397.81M, which demonstrates strong financial flexibility by providing ample liquidity to fund R&D initiatives or return capital to shareholders without relying on external financing. Profitability is evidenced by a gross margin of 62.7%, indicating high pricing power and efficient production relative to the cost of goods sold, supported by an operating margin of 28.2% that reflects effective internal cost management. The balance sheet presents a conservative profile with cash reserves of $1.48B significantly outweighing total debt of $471.30M, a position further confirmed by a debt-to-equity ratio of 14.49. Short-term liquidity is robust, as indicated by a current ratio of 3.39, which suggests the firm can easily cover its short-term liabilities with its current assets. Management effectiveness is highlighted by a return on equity of 16.4% and a return on assets of 9.5%, metrics that demonstrate the efficient generation of profits relative to the shareholders' investment and the company's total asset base.
Valuation Assessment
The trailing twelve-month P/E ratio stands at 27.77, while the forward P/E is projected at 13.34. The notable difference between these two metrics implies that the market expects earnings growth to accelerate significantly in the future, allowing the stock to appear cheaper on a forward basis compared to its historical earnings. The price-to-book ratio is 3.99, indicating that the market values the company at nearly four times its book value, which suggests a significant premium attributed to its intangible assets, such as intellectual property and brand value. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 4.55 and an EV/EBITDA of 18.01, suggesting that investors are willing to pay a premium for revenue and earnings generation in this specialized drug manufacturing sector. Regarding price volatility, the stock's 52-week high is $160.18 and its 52-week low is $84.23. Without a specific current price provided in the available facts to calculate the exact percentage, the trading range defines the historical volatility envelope within which the asset has fluctuated over the past year. The beta value is 0.36, which indicates that the stock's price movements are significantly less volatile than the broader market, offering a lower-risk profile relative to the overall equity market.
Growth & Income
The company has demonstrated robust expansion with revenue growth of 28.3% year-over-year and earnings growth of 47.7% year-over-year. Earnings are growing faster than revenue, which implies improving operational leverage and efficiency, allowing net income to expand at a rate that outpaces the top-line growth. Neurocrine Biosciences does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company chooses to reinvest all of its earnings back into the business to fuel further growth and development rather than distributing cash to shareholders. This reinvestment strategy is typical for pharmaceutical companies in the specialty and generic space that prioritize long-term pipeline expansion over immediate income distribution. The overall growth and income profile is characterized by high single-digit to low double-digit growth rates in earnings, supported by a strong balance sheet that enables capital allocation toward innovation rather than shareholder payouts.